

SECOND EDITION

OXFORD AMERICAN HANDBOOK OF
ONCOLOGY

Evidence-based guidance on clinical decision making,
treatment options, and therapeutic regimens

Algorithms, practice guidelines, highlight tables, and
landmark references

Covers cancer biology, genetics, prevention and
screening, and complications and supportive care

Edited by Gary H. Lyman

with Jim Cassidy

Donald Bissett

Roy A.J. Spence

Miranda Payne

Oxford American Handbook of Oncology

Second Edition

Edited by

**Gary H. Lyman, M.D., M.P.H.,
F.R.C.P. (Edin)**

Co-Director, Fred Hutchinson Institute for Cancer
Outcomes Research

Divisions of Public Health Science and Clinical Research
Fred Hutchinson Cancer Research Center

Professor of Medicine, University of Washington School of
Medicine

Adjunct Professor, Schools of Public Health and Pharmacy,
University of Washington

Seattle, Washing

with

Jim Cassi

Donald Bissett

Roy A.J. Spence

Miranda Payne

OXFORD
UNIVERSITY PRESS

OXFORD

UNIVERSITY PRESS

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.

Oxford New York

Auckland Cape Town Dar es Salaam Hong Kong Karachi

Kuala Lumpur Madrid Melbourne Mexico City Nairobi

New Delhi Shanghai Taipei Toronto

With offices in

Argentina Austria Brazil Chile Czech Republic France Greece

Guatemala Hungary Italy Japan Poland Portugal Singapore

South Korea Switzerland Thailand Turkey Ukraine Vietnam

Oxford is a registered trademark of Oxford University Press
in the UK and certain other countries.

Published in the United States of America by

Oxford University Press

198 Madison Avenue, New York, NY 10016

Copyright © 2015 by Oxford University Press, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by license, or under terms agreed with the appropriate reproduction rights organization. Inquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above.

You must not circulate this work in any other form
and you must impose this same condition on any acquirer.

Adapted from *Oxford Handbook of Oncology*, Second Edition by Jim Cassidy,
Donald Bissett, Roy A.J. Spence, and Miranda Payne, 2006.

Library of Congress Cataloging-in-Publication Data

Oxford American handbook of oncology / edited by Gary H. Lyman ; with Jim
Cassidy, Donald Bissett, Roy A.J. Spence, Miranda Payne.—Second edition.

p. ; cm.—(Oxford American handbooks)

Handbook of oncology

Based on (work): *Oxford handbook of oncology* / edited by Jim Cassidy ... [et al.].
3rd ed. 2010.

Includes bibliographical references and index.

ISBN 978-0-19-992278-9 (alk. paper)

I. Lyman, Gary H. (Gary Herbert), 1946–, editor. II. Cassidy, Jim, 1958–, editor.

III. Bissett, Donald, editor. IV. Spence, Roy A. J. (Roy Archibald Joseph), editor.

V. Payne, Miranda, editor. VI. *Oxford handbook of oncology*. Based on (work):

VII. Title: *Handbook of oncology*. VIII. Series: *Oxford American handbooks*.

[DNLM: 1. Neoplasms—Handbooks. QZ 39]

RC262.5

616.99'4—dc23

2014024777

9 8 7 6 5 4 3 2 1

Printed in the United States of America

on acid-free paper

This material is not intended to be, and should not be considered, a substitute for medical or other professional advice. Treatment for the conditions described in this material is highly dependent on the individual circumstances. Although this material is designed to offer accurate information with respect to the subject matter covered and to be current as of the time it was written, research and knowledge about medical and health issues are constantly evolving and dose schedules for medications are being revised continually, with new side effects recognized and accounted for regularly. Readers must, therefore, always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulation. Oxford University Press and the authors make no representations or warranties to readers, express or implied, about the accuracy or completeness of this material, including, without limitation, that they make no representation or warranties about the accuracy or efficacy of the drug dosages mentioned in the material. The authors and the publishers do not accept, and expressly disclaim, any responsibility for any liability, loss, or risk that may be claimed or incurred as a consequence of the use and/or application of any of the contents of this material.

The Editor and Authors dedicate this book to our patients, our families,
and our colleagues

Preface

Welcome to the second edition of the *Oxford American Handbook of Oncology*. Based on the successful *Oxford Handbook of Oncology*, this volume has been updated and revised from the first edition by the multiple authors from the Fred Hutchinson Cancer Research Center and the University of Washington as well as Duke University and the Duke Cancer Institute. The updated version includes recently introduced diagnostic, prognostic, and therapeutic strategies emerging since the first edition. As before, the authors have particularly sought to approach each topic from a practical standpoint with pointers to effective diagnostic, staging, and management plans. It will serve as an information source for healthcare providers who come in contact with a broad range of oncology patients, as well as subspecialists who occasionally see cancer patients outside of their primary focus. It is also designed to be a resource for advanced residents and fellows, as well as others who are training or retraining in disciplines related to oncology. The editor and authors hope that this edition may also spark interest in others to pursue further training and focus both clinical and research interest on this fascinating and challenging group of diseases. I would like to thank all of the contributors for their outstanding efforts, and particularly Ms Andrea Parsek and Mrs. Nancy Thomasson, who have greatly assisted all of us in making this final volume one that we can all be proud of. And to our readers: you can thank us most by replying with comments and suggestions that can help us improve future volumes of this series, to make it more useful in your daily care of patients with cancer.

Gary Lyman

*Fred Hutchinson Institute for
Cancer Outcomes Research Seattle, WA*

Acknowledgments

The editor and authors would like to sincerely thank Ms. Andrea Parsek and Mrs. Nancy Thomasson for their outstanding support and assistance in the completion of this book.

List of contributors

Amy P. Abernethy, MD

Duke University
Medical Oncology

Ivy Altomare, MD

Duke University
Medical Oncology

Carrie Anders, MD

Duke University
Medical Center

Carey K. Anders, MD

Department of Medicine
University of North Carolina

Andrew J. Armstrong, MD

Duke University
Medical Oncology

Sally Barbour, MD

Duke University
Cancer Center Administration

Jason Cory Barnett, MD

Duke University
Medicine

Rhonda L. Bitting, MD

Duke University
Medical Center

Anne W. Beaven, MD

Duke University
Medical Oncology

Johanna C. Bendell, MD

Duke University
Medical Oncology

Andrew Berchuck, MD

Duke University
Ob/gyn Oncology

Gerard Blobe, MD, PhD

Duke University
Medical Oncology

Karen E. Bullock, MD

Duke University
Medicine

Jeffrey Crawford, MD

Duke University
Medical Oncology

Thomas A. D'Amico, MD

Duke University
Thoracic Surgery

Carlos M. deCastro, MD

Duke University
Medical Oncology

Annick Desjardins, MD

Duke University
Medical Neurology

Louis F. Diehl, MD

Duke University
Medical Oncology

Phuong L. Doan, MD

Duke University
Medicine

Ashley Engemann, MD

Duke University
Cellular Therapy

Phillip Febbo, MD

Chief Medical Office
Genomic Health

Daphne Friedman, MD

Duke University
Medicine

Christina Gasparetto, MD

Duke University
Cellular Therapy

Daniel George, MD

Duke University
Medical Oncology

Jon Gockerman, MD

Duke University
Medical Oncology

Ranjit Goudar, MD

Duke University
Medical Center

Erika Hamilton, MD

Sarah Cannon Research Institute

Christina I. Herold, MD

Beth Israel Deaconess Medical
Center
Instructor in Medicine Harvard
Medical School

Bridget F. Koontz, MD

Duke University
Radiation Oncology

Nicole M. Kuderer, MD

Department of Medicine
University of Washington School
of Medicine

Kathleen Lambert, MD

Duke University
Medicine

Mark C. Lanasa, MD

Associate Medical Director
MedImmune

Jacob Laubach, MD

Dana Farber Cancer Institute
Instructor in Medicine
Harvard Medical School

Thomas W. LeBlanc, MD

Duke University
Medicine

Matthew McKinney, MD

Duke University
Medical Center

Prateek Mendiratta, MD

Duke University
Medicine

Joseph Moore, MD

Duke University
Medical Oncology and
Transplant SVC

Michael Morse, MD

Duke University
Medical Oncology

Jeanne Palmer, MD

Duke University
Medicine

Jeffrey Peppercorn, MD

Duke University
Medical Oncology

Arati V. Rao, MD

Duke University
Medical Oncology

Neal Ready, MD, PhD

Duke University
Medical Oncology

Richard Redman, MD

Duke University
Medical Center

Lindsay A. M. Rein, MD

Duke University
Medicine

Richard F. Riedel, MD

Duke University
Medical Oncology

David Rizzieri, MD

Duke University
Medical Oncology

April K. S. Salama, MD

Duke University
Medicine

Heather Shaw, MD

Duke University
Medical Oncology

Carling Ursem, MD

Duke University
Medicine

James Vredenburgh, MD

Duke University
Medical Oncology

J. Brice Weinberg, MD

Duke University
Medical Oncology

Christopher G. Willett, MD

Duke University
Radiation Oncology

S. Yousuf Zafar, MD

Duke University
Radiation Oncology

List of color plates

- Plate 1 IMRT plan for a left-sided oropharyngeal head and neck cancer
- Plate 2 Benign pigmented lesion
- Plate 3 Benign nevus close-up
- Plate 4 Malignant melanoma close-up
- Plate 5 Malignant melanoma close-up
- Plate 6 Squamous cell carcinoma
- Plate 7 Basal cell carcinoma

Contents

List of contributors *xiii*

List of color plates *xvii*

Part I Background

- | | | |
|---|---------------------------|----|
| 1 | Molecular cancer biology | 3 |
| 2 | Etiology and epidemiology | 15 |

Part II Cancer prevention and screening

- | | | |
|---|-------------------|----|
| 3 | Cancer prevention | 29 |
| 4 | Cancer screening | 45 |
| 5 | Genetic screening | 51 |

Part III Principles of management

- | | | |
|----|---|-----|
| 6 | Principles of cancer treatment | 61 |
| 7 | Surgical oncology | 65 |
| 8 | Principles of radiation oncology | 81 |
| 9 | Principles of chemotherapy | 101 |
| 10 | Hematopoietic stem cell transplantation | 151 |
| 11 | Hormone therapy | 165 |
| 12 | Targeted therapies | 175 |
| 13 | Gene therapy and immunotherapy for cancer | 185 |
| 14 | Complementary and alternative medicine | 195 |
| 15 | Clinical trials | 205 |

Part IV Complications and supportive care

- | | | |
|----|---------------------|-----|
| 16 | Anemia and fatigue | 215 |
| 17 | Febrile neutropenia | 229 |
| 18 | Pain management | 251 |

19	Venous thromboembolism	271
20	Metabolic emergencies	289
21	Paraneoplastic syndromes	303
22	Superior vena cava syndrome and raised intracranial pressure	321
23	Spinal cord compression	331
24	Other obstructive complications	337
25	Late effects of cancer treatment	351
26	End-of-life care	363
	Part V Specific cancers	
27	Thoracic cancers	395
28	Breast cancer	429
29	Gastrointestinal cancer I: esophagus, stomach, small intestine, carcinoid	465
30	Gastrointestinal cancer II: pancreas, biliary tract, hepatocellular	483
31	Gastrointestinal cancer III: colorectal, anus	499
32	Endocrine cancers	513
33	Genitourinary cancers I: renal, bladder, ureter, penile carcinomas	535
34	Genitourinary cancers II: prostate cancer	563
35	Genitourinary cancers III: testicular cancer	589
36	Gynecological cancer	605
37	Tumors of the central nervous system	625
38	Head and neck cancers	643
39	Cutaneous malignancies	667
40	Soft tissue and bone sarcomas	687
41	Acute leukemia	717
42	Chronic leukemias and myelodysplastic syndromes	729

43	Multiple myeloma	749
44	Malignant lymphoma	767
45	Cancer of unknown primary	789
Appendix		801
Index		821

Part I

Background

- 1 Molecular cancer biology
- 2 Etiology and epidemiology

3

15

Molecular cancer biology

Gerard Blobe
Phillip Febbo

Introduction to cancer 4

Molecular alterations in cancer 6

Cancer biology 10